undamentalytics Newsletter
Sign in

Biorestorative Therapies, Inc. cash flow statement

In fiscal 2025, Biorestorative Therapies, Inc.'s operations generated −$10.8m of cash; it spent $116,069 on capital projects, leaving free cash flow of −$10.9m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMMar 2026
Cash from operations−3−3−3−3−3−5−4−5−7−2−3−6−6−8−11−12
Depreciation and amortisation0000000000000000
Stock-based pay021123422123138332
Capital spending000000000—00000—
Free cash flow−3−3−3−3−4−5−4−5−7—−3−6−7−8−11—
Free cash flow after stock pay−3−5−3−5−5−8−7−8−9—−26−19−14−11−14—
Share buybacks000———————————0—
Shares issued02————0——0——0—3—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: BRTX vs CRVOBRTX vs CRDFBRTX vs CLNN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Biorestorative Therapies, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Biorestorative Therapies, Inc.